Welcome to our dedicated page for AIM ImmunoTech SEC filings (Ticker: AIM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on AIM ImmunoTech's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into AIM ImmunoTech's regulatory disclosures and financial reporting.
AIM ImmunoTech Inc., an immuno‑pharma company developing Ampligen and Alferon, reported very limited Q2 2026 revenue of $26 thousand and an operating loss of $3.5 million, compared with a $2.6 million operating loss a year earlier. Net loss for the quarter was $3.8 million, and $6.8 million for the first half of 2026.
Cash and cash equivalents increased to $9.9 million at June 30, 2026 from $3.0 million at December 31, 2025, driven by $14.4 million of net cash provided by equity offerings and warrant exercises in the first six months. Total assets were $12.7 million, with stockholders’ equity improving to $7.7 million from a $9.8 million deficit.
Management states that recurring losses and operating cash outflows of $7.3 million for the first half raise substantial doubt about the company’s ability to continue as a going concern for at least one year. AIM continues to advance Ampligen, including a fully enrolled Phase 2 DURIPANC trial in metastatic pancreatic cancer and preparatory work for a potential Phase 3 study.
AIM ImmunoTech Inc. entered into a Proposal Agreement with Sterling Pharma Solutions on July 31, 2026. Under this arrangement, Sterling will manufacture additional batches of the polynucleotide drug substances PolyI and Poly C12U and transfer associated test methods at its Dudley, UK facility. These materials serve as polymer precursors for producing the drug Ampligen.
The estimated cost to AIM is approximately $1.5 million, payable over 12 months. AIM plans to use the manufactured product in ongoing and future clinical trials, including potentially a Phase 3 clinical trial for metastatic pancreatic cancer.
AIM also outlined timing requirements for stockholders wishing to nominate directors or bring other business at the 2026 annual meeting outside Rule 14a-8. Notices must be received between August 18, 2026 and 5:00 p.m. local time on September 17, 2026, with a separate Rule 14a-19 universal proxy notice due by October 19, 2026.
AIM ImmunoTech Inc. is terminating its Equity Distribution Agreement with Maxim Group LLC, which allowed sales of common stock in an at the market offering under Rule 415. Notice of mutual termination was given on July 31, 2026, and the termination is effective August 15, 2026. The company will not incur any termination penalties.
Under this program, from April 1, 2025 to July 31, 2026, AIM ImmunoTech sold 3,200,736 shares of common stock for aggregate gross proceeds of approximately $2.8 million. The company does not intend to issue or sell any additional shares under the Agreement before termination, and after termination it may not offer or sell any additional shares under that Agreement or the related prospectus and prospectus supplement.
AIM ImmunoTech Inc. held a Special Meeting of Stockholders on July 15, 2026, with 10,671,690 of 27,724,245 common shares represented, or 38.5%, exceeding the 33 and 1/3% quorum requirement. Stockholders approved several proposals tied to future equity issuance and capital structure flexibility.
They authorized, for NYSE American Company Guide Sections 713(a) and 713(b) compliance, the issuance of more than 19.99% of outstanding common stock upon exercise of Class H, Class I and Class J common stock purchase warrants, and upon conversion or other satisfaction of promissory notes dated February 16, 2024 and November 18, 2025. Stockholders also approved amendments permitting the Board, at its option, to implement a reverse stock split at a ratio of up to 1-for-25, and approved the ability to adjourn the Special Meeting to a later date or time to solicit additional proxies if necessary.
AIM ImmunoTech Inc. has called a virtual special stockholder meeting on July 15, 2026 to approve several financing-related actions and a potential reverse stock split. Holders of 27,724,245 shares of common stock as of June 15, 2026 may vote.
Stockholders are asked to approve issuances of more than 19.99% of outstanding shares tied to Class H, I and J warrants and to conversions of two promissory notes, in each case to comply with NYSE American Company Guide Sections 713(a) and 713(b). The company discloses that full cash exercises of these warrants could bring in additional gross proceeds of about $8.9 million (Class H), $4.9 million (Class I) and $5.3 million (Class J).
Another proposal would authorize the board, at its option, to implement a reverse stock split at a ratio of up to 1-for-25. The proxy explains that existing cash and investments are not expected to fund 12 months of operations and states that failure to raise additional capital in the very near term could force substantial cutbacks or even a voluntary bankruptcy filing. The board unanimously recommends voting “FOR” all seven proposals.
AIM ImmunoTech Inc. registers for resale up to 13,077,089 shares of Common Stock held by selling stockholders, consisting of PIPE Shares, Pre-Funded Warrant Shares, Class J Warrant Shares and June Offering Placement Agent Warrant Shares. The prospectus states the resale is by the selling stockholders and that AIM will not receive proceeds from resale; the company would receive proceeds only if certain warrants are exercised for cash. The filing bases outstanding share counts on 27,724,245 shares outstanding as of June 12, 2026 and shows a pro forma outstanding amount of 40,801,334 shares assuming full exercise of the referenced warrants. The offering arose from a June 10, 2026 registered direct offering and concurrent private placement (the “June Offering”), which included registered shares, PIPE Shares, Pre-Funded Warrants and Class J Warrants.
AIM ImmunoTech Inc. registered for resale up to 31,287,933 shares of Common Stock by the identified Selling Stockholders, consisting of shares issuable upon exercise of Class H and Class I Warrants and placement agent warrants. The prospectus states the company will not receive proceeds from resale by the Selling Stockholders; cash proceeds of approximately $14.5 million would result only if all Warrants and Placement Agent Warrants are exercised for cash. The filing lists 24,328,623 shares outstanding as of May 29, 2026 and discloses post‑exercise outstanding shares would be 55,616,556 assuming full exercise.
AIM ImmunoTech Inc. has filed to register up to 13,077,089 shares of common stock for resale by existing selling stockholders, including shares issuable from PIPE shares, Pre-Funded Warrants, Class J Warrants and June offering placement agent warrants. The company is not selling any shares in this transaction and will not receive proceeds from stockholder resales.
If all related Pre-Funded, Class J and placement agent warrants are exercised for cash, AIM would receive approximately $5.5 million in gross proceeds for general corporate purposes and working capital. In that scenario, common shares outstanding would rise from 27,724,245 as of June 12, 2026 to 40,801,334, an increase of about 47.17%, and the prospectus highlights significant dilution and NYSE American listing and penny stock risks.